Bonesupport Holding AB

Bonesupport Holding AB

Health CarePharmaceuticals & Biotechnology
  • Price (SEK)39.10
  • Today's Change1.20 / 3.17%
  • Shares traded71.77k
  • 1 Year change97.47%
  • Beta--
Data delayed at least 15 minutes, as of Jan 24 2020 17:00 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.

  • Revenue in SEK (TTM)132.37m
  • Net income in SEK-167.14m
  • Incorporated--
  • Employees80.00
  • Location
    Bonesupport Holding ABScheelevagen 19 ALUND 223 70SwedenSWE
  • Phone+46 462865370
  • Fax+46 462865371
  • Websitehttps://www.bonesupport.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Diamyd Medical AB1.57m-36.61m1.24bn----20.49--790.19-0.5487-0.54870.02430.90760.0243--9.74---56.68-53.06-67.68-61.13-----2,334.82-3,556.02---891.930.00--115.9828.7616.71------
IRLAB Therapeutics AB44.00k-88.36m1.24bn22.00--8.20--28,262.83-2.18-2.180.00113.520.0002--0.00771,760.00-43.52---47.27-------200,818.20-----454.460.00---83.49---31.79------
Bergenbio ASA11.65m-203.87m1.33bn26.00--4.56--114.48-3.51-3.510.20054.530.0302--0.6252459,041.70-52.76---58.04-------1,749.71------0.0002-------5.24------
XSpray Pharma AB (publ)206.00k-40.74m1.39bn13.00--4.59--6,725.04-2.75-2.750.013918.010.0008--0.067813,733.33-15.57---16.21-------19,774.27------0.0192---16.57---67.17------
Cantargia AB0.00-102.39m1.46bn11.00--8.20-----1.48-1.480.002.450.00----0.00-49.98-49.51-56.66-57.92------------0.00-------51.30------
Q linea AB1.31m-154.77m1.50bn64.00--3.74--1,147.54-7.36-7.360.06117.230.0052--41.4624,641.51-61.61---68.98---1,615.70---11,850.92------0.002---28.93---89.09------
Genovis AB58.26m11.51m1.56bn23.00135.9642.86104.0826.860.18240.18240.92320.57871.24----2,912,799.0024.54-53.6331.34-73.8466.700.38719.76-68.35--15.570.1136--51.1731.1478.48---5.05--
Nordic Nanovector ASA0.00-406.61m1.61bn46.00--4.95-----7.23-,984.18----0.0251---100.00---14.96--48.77--
Ultimovacs ASA0.00-51.29m1.64bn17.00--3.33-----2.36-2.360.0016.770.00----0.00-14.20---14.67--------------0.0073-------68.38------
Swedencare AB (publ)120.56m29.93m1.69bn33.0056.3713.5352.1014.021.901.907.647.910.92652.656.754,018,800.0023.0021.2726.4625.7374.2073.3324.8320.843.56146.310.00--15.9640.2537.06197.46----
Infant Bacterial Therapeutics AB0.00-42.93m1.76bn8.00--3.38-----3.82-3.820.0047.920.00----0.00-7.56-17.29-7.67-18.00-------28,727.13----0.00---100.00---12.31------
Photocure ASA228.29m-23.98m1.92bn71.00--10.93--8.43-1.05-1.059.987.640.96991.1210.763,040,254.00-10.19-7.27-12.43-8.3590.9192.74-10.51-13.113.18--0.0455--20.2816.77-5.80--7.13--
Bonesupport Holding AB132.37m-167.14m2.03bn80.00--12.66--15.35-3.23-3.232.563.090.44290.61926.101,838,486.00-55.92---68.17--85.47---126.26--2.68-2,303.330.0657---25.27---36.89------
Oasmia Pharmaceutical AB2.13m-168.19m2.17bn55.00--4.07--1,019.42-0.6043-0.60430.00721.190.0036-0.0460.803735,450.00-28.05-27.77-39.47-43.44129.90346.37-7,906.91-5,370.330.5008-11.650.1831---37.52101.23-71.08---19.54--
Orexo AB833.80m231.90m2.41bn130.0010.603.599.132.896.546.5423.5519.350.60560.79312.866,463,566.0016.84-1.4426.36-2.1084.9077.8027.80-2.282.04--0.3419--21.6612.77494.40---43.66--
PCI Biotech Holding ASA10.84m-72.06m2.62bn13.00--8.87--241.48-1.86-1.860.28857.480.0604--0.7216788,230.80-40.14-48.98-45.98-58.77-----664.92-369.36----0.0048---6.497.4918.82------
Data as of Jan 24 2020. Currency figures normalised to Bonesupport Holding AB's reporting currency: Swedish Krona SEK

Institutional shareholders

35.22%Per cent of shares held by top holders
HolderShares% Held
Swedbank Robur Fonder ABas of 30 Jun 20194.09m7.87%
Tredje AP-fondenas of 30 Jun 20194.05m7.79%
Fj�rde AP-fondenas of 30 Jun 20192.49m4.80%
Lundbeckfond Invest A/Sas of 13 Nov 20192.26m4.36%
Lancelot Asset Management ABas of 30 Jun 20191.65m3.17%
AMF Fonder ABas of 30 Jun 20191.50m2.89%
AXA Investment Managers (Paris) SAas of 30 Jun 20191.01m1.94%
Alfred Berg Kapitalf�rvaltning ABas of 29 Nov 2019530.48k1.02%
Xact Kapitalf�rvaltning ABas of 31 Dec 2019425.44k0.82%
E. �hman J :or Fonder ABas of 30 Jun 2018300.00k0.58%
More ▼
Data from 30 Jun 2019 - 31 Dec 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.